Clinical Trial Update: A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lurbinectedin alone or with gemcitabine versus docetaxel in second-line non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Gemcitabine (Gemcitabine)
• Lurbinectedin (lurbinectedin)

Snippet

Sponsor: PharmaMar | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2019-09-24